Abstract: The invention is that of systems and methods for controllerless and distributed network connections to servers on a network by remote clients seeking their services. The invention comprises a server database where servers within a server group identified by a groupname may post unique identifiers (UIDs) for retrieval by group clients configured with the groupname, which may query the server database for server connection information such as uptime, downtime, and congestion in order to select a server for a preferential connection based on an overall availability profile as determined by the group client. The methods described herein eliminate a separate controller and thereby eliminate the single point of failure (SPOF) represented by connection controllers and load balancers in a network as are common in the current state of the art.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The invention is that of systems and methods for communications between one or more networks and subsequently network devices configured with a networking application for processing network based communications when the devices are on different logical and physical networks. The methods herein involve translation of remote IP addresses of LAN devices to addresses comprising headend network prefixes, to allow for LAN extension of remote to headend networks and communications between devices on the disparate networks. Data packets from a remote LAN interface are transferred to an outbound interface once translated, then forwarded via a formed bridged tunnel link to a headend network device. A server comprising a local LAN and outbound interface is further configured with a NAT module for IP address translation and an optional security module for additional authenticity verification of remote devices attempting to penetrate the headend network.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect described herein relates to substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The present description relates' to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The invention described herein is that of systems and methods for agentless identity-based authentication of network-enabled devices for control of network traffic to and from each device based on identity. The invention leverages X.509 certificates associated with network devices and comprises at least one querying device in communication with at least target device and optionally at least one intermediate device, such as but not limited to a switching device that can interface with the target device and enable the querying device to query the target device to obtain an X.509 certificate and any extensions, then dictate switching actions, which may be carried out by the querying device according to instructions provided by a switching module residing on the querying device or located external to the querying device. The systems and methods described herein are suitable for validation of the identities of fixed application devices to prevent unauthorized network access.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), Formula (II), Formula (III), or Formula (IV), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The invention described herein is that of systems and methods for agentless identity-based authentication of network-enabled devices for control of network traffic to and from each device based on identity. The invention leverages X.509 certificates associated with network devices and comprises at least one querying device in communication with at least target device and optionally at least one intermediate device, such as but not limited to a switching device that can interface with the target device and enable the querying device to query the target device to obtain an X.509 certificate and any extensions, then dictate switching actions, which may be carried out by the querying device according to instructions provided by a switching module residing on the querying device or located external to the querying device. The systems and methods described herein are suitable for validation of the identities of fixed application devices to prevent unauthorized network access.

Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The invention presented herein is a system and method for automatically discovering communication capabilities for direct communication between endpoints across one or more unknown networks, the system comprising: a plurality of network enabled endpoints configured with a module in wireless communication with a management database, the module configured to establish a communication path for direct communication between the network-enabled endpoints, independent of a NAT router.

Abstract: A tether line is mounted in a retriever and, when a water vessel is launched into the water, the retriever applies a tension force to the tether line. After the water vessel is launched, the tension on the tether line pulls the water vessel from its launched floating position towards the stationary object. The retriever is rotatably mounted on the water vessel or the stationary object such that it will pivot around a vertical axis and point in a direction towards and along the tether line. A spool mounted on the structural unit holds the tether line, and an electrical or mechanical motor, such as a spring B-motor, places a torque on the spool and a tension on the tether line. After the water vessel is launched, the tension force from the motor pulls the water vessel from a launched position to the stationary object.

Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.